Expert Answers About COVID-19 Treatment With Neutralizing Monoclonal Antibodies
Neutralizing monoclonal antibodies received emergency use authorization to treat mild to moderate COVID-19 with the aim of reducing severe illness and hospitalization in at-risk patients. This 30-minute program addresses clinician questions about these therapies and their use. Gain valuable insights from an interprofessional team of presenters who discuss the science and practical issues of using monoclonal antibodies to treat patients with COVID-19 in outpatient settings.
Use of Neutralizing Monoclonal Antibodies in Ambulatory Patients With COVID-19
Engage with a multidisciplinary, interprofessional panel of experts on COVID-19 infusion therapies with virus-neutralizing monoclonal antibodies (mAbs). This activity features a clinical discussion of the Emergency Use Authorization criteria and data from real-world use of mAbs in ambulatory patients. Learn how this treatment reduces the chance of patients with COVID-19 developing severe illness and what could be done to effectively implement the outpatient delivery of mAbs to patients with COVID-19 in your practice.
PsA + COVID-19: Connecting on Patient Care During a Pandemic
This 30-minute online activity is presented by a nationally and internationally recognized rheumatology expert who will review recommendations relevant to treatment of PsA by American College of Rheumatology, National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, and European League Against Rheumatism. The presenter also discusses how COVID-19 has impacted rheumatology community views on the use of biologic therapies.
Explore Outcomes from Our Past ActivitiesLearn More
“Team members planning meetings were well-organized and concise. They were also highly adaptable, making relevant changes in a timely manner to meet the needs of the audience.”